AMELY

Across TCGA pan-cancer cohorts, AMELY mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated AMELY data layer compared with 7 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher AMELY mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AMELY expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where AMELY mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.726	1.000	.001	27	view →
UCEC	DFS	Median	All	1.000	0.936	.022	14	view →
PDAC	OS	Quartile	II,III,IV	0.252	0.609	.004	12	view →
GBM	OS	Tertile	All	0.653	0.260	.010	8	view →
COAD	DFS	Median	IV	0.493	0.944	.031	6	view →
LSCC	DFS	Median	II,III,IV	0.819	0.555	.021	6	view →
HNSC	OS	Median	II,III,IV	1.000	0.953	.023	2	view →
LUAD	OS	Median	All	0.950	0.803	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

AMELY–CCRCC (DFS)

Open the CCRCC breakdown →